Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...

A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.

Shares of Moderna fell sharply Friday after the company lowered the top end of its full-year revenue outlook because of a ...

Moderna cut 2025 revenue by $300m after delaying UK Covid vaccine shipments to 2026, as Q2 results beat forecasts with ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

The biotech company reported second-quarter financial results on Friday ahead of market open, a day after announcing plans to ...

Live Updates Live Coverage Updates appear automatically as they are published. Moderna Still Sickly 9:49 am In further ...

Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.

The CDC has revamped its work groups in a key vaccine advisory panel, excluding certain expert groups from the ...